- -

Profile of the Roche cobas (R) EGFR mutation test for non-small cell lung cancer

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

  • Estadisticas de Uso

Profile of the Roche cobas (R) EGFR mutation test for non-small cell lung cancer

Mostrar el registro sencillo del ítem

Ficheros en el ítem

dc.contributor.author Malapelle, Umberto es_ES
dc.contributor.author Sirera Pérez, Rafael es_ES
dc.contributor.author Jantus-Lewintre, Eloisa es_ES
dc.contributor.author Reclusa, P. es_ES
dc.contributor.author Calabuig-Farinas, S. es_ES
dc.contributor.author Blasco, Ana es_ES
dc.contributor.author Pisapia, P. es_ES
dc.contributor.author Rolfo, C. es_ES
dc.contributor.author Camps, Carlos es_ES
dc.date.accessioned 2020-07-14T03:31:14Z
dc.date.available 2020-07-14T03:31:14Z
dc.date.issued 2017 es_ES
dc.identifier.issn 1473-7159 es_ES
dc.identifier.uri http://hdl.handle.net/10251/147918
dc.description.abstract [EN] Introduction: The discovery of driver mutations in non-small cell lung cancer (NSCLC) has led to the development of genome-based personalized medicine. Fifteen to 20% of adenocarcinomas harbor an epidermal growth factor receptor (EGFR) activating mutation associated with responses to EGFR tyrosine kinase inhibitors (TKIs). Individual laboratories' expertise and the availability of appropriate equipment are valuable assets in predictive molecular pathology, although the choice of methods should be determined by the nature of the samples to be tested and whether the detection of only well-characterized EGFR mutations or rather, of all detectable mutations, is required.Areas covered: The EGFR mutation testing landscape is manifold and includes both screening and targeted methods, each with their own pros and cons. Here we review one of these companion tests, the Roche cobas (R) EGFR mutation test v2, from a methodological point of view, also exploring its liquid-biopsy applications.Expert commentary: The Roche cobas (R) EGFR mutation test v2, based on real time RT-PCR, is a reliable option for testing EGFR mutations in clinical practice, either using tissue-derived DNA or plasma-derived cfDNA. This application will be valuable for laboratories with whose purpose is purely diagnostic and lacking high-throughput technologies. es_ES
dc.description.sponsorship This work was partially supported by FEDER, CIBERONC, grant number [CB16/12/00350]. es_ES
dc.language Inglés es_ES
dc.publisher Taylor & Francis es_ES
dc.relation.ispartof Expert Review of Molecular Diagnostics es_ES
dc.rights Reserva de todos los derechos es_ES
dc.subject EGFR es_ES
dc.subject Cobas (R) es_ES
dc.subject Liquid biopsy es_ES
dc.subject Companion diagnostic es_ES
dc.subject Mutation es_ES
dc.subject Resistance es_ES
dc.subject TKIs es_ES
dc.subject.classification BIOLOGIA CELULAR es_ES
dc.title Profile of the Roche cobas (R) EGFR mutation test for non-small cell lung cancer es_ES
dc.type Artículo es_ES
dc.identifier.doi 10.1080/14737159.2017.1288568 es_ES
dc.relation.projectID info:eu-repo/grantAgreement/MINECO//CB16%2F12%2F00350/ES/CANCER/ es_ES
dc.rights.accessRights Cerrado es_ES
dc.contributor.affiliation Universitat Politècnica de València. Departamento de Biotecnología - Departament de Biotecnologia es_ES
dc.description.bibliographicCitation Malapelle, U.; Sirera Pérez, R.; Jantus-Lewintre, E.; Reclusa, P.; Calabuig-Farinas, S.; Blasco, A.; Pisapia, P.... (2017). Profile of the Roche cobas (R) EGFR mutation test for non-small cell lung cancer. Expert Review of Molecular Diagnostics. 17(3):209-215. https://doi.org/10.1080/14737159.2017.1288568 es_ES
dc.description.accrualMethod S es_ES
dc.relation.publisherversion https://doi.org/10.1080/14737159.2017.1288568 es_ES
dc.description.upvformatpinicio 209 es_ES
dc.description.upvformatpfin 215 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion es_ES
dc.description.volume 17 es_ES
dc.description.issue 3 es_ES
dc.identifier.pmid 28129709 es_ES
dc.relation.pasarela S\352272 es_ES
dc.contributor.funder European Regional Development Fund es_ES
dc.contributor.funder Ministerio de Economía y Competitividad es_ES
dc.description.references Ridge, C., McErlean, A., & Ginsberg, M. (2013). Epidemiology of Lung Cancer. Seminars in Interventional Radiology, 30(02), 093-098. doi:10.1055/s-0033-1342949 es_ES
dc.description.references Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., … Fukuoka, M. (2009). Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine, 361(10), 947-957. doi:10.1056/nejmoa0810699 es_ES
dc.description.references Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., … Haber, D. A. (2004). Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 350(21), 2129-2139. doi:10.1056/nejmoa040938 es_ES
dc.description.references Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., … Sanchez, J. M. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology, 13(3), 239-246. doi:10.1016/s1470-2045(11)70393-x es_ES
dc.description.references Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., … Sequist, L. V. (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet Oncology, 16(2), 141-151. doi:10.1016/s1470-2045(14)71173-8 es_ES
dc.description.references Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., … Ranson, M. (2015). AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer. New England Journal of Medicine, 372(18), 1689-1699. doi:10.1056/nejmoa1411817 es_ES
dc.description.references Pirker, R., Herth, F. J. F., Kerr, K. M., Filipits, M., Taron, M., Gandara, D., … Stahel, R. (2010). Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop. Journal of Thoracic Oncology, 5(10), 1706-1713. doi:10.1097/jto.0b013e3181f1c8de es_ES
dc.description.references Malapelle, U., Russo, S., Pepe, F., Sgariglia, R., De Luca, C., Bellevicine, C., … Troncone, G. (2013). EGFR mutation detection by microfluidic technology: a validation study. Journal of Clinical Pathology, 66(11), 982-984. doi:10.1136/jclinpath-2013-201730 es_ES
dc.description.references Malapelle, U., Bellevicine, C., De Luca, C., Salatiello, M., De Stefano, A., Rocco, D., … Troncone, G. (2013). EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. Cancer Cytopathology, 121(10), 552-560. doi:10.1002/cncy.21322 es_ES
dc.description.references Giannini, R., Lupi, C., Sensi, E., Alì, G., Proietti, A., Boldrini, L., … Fontanini, G. (2016). EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. Oncology Reports, 36(2), 1166-1172. doi:10.3892/or.2016.4874 es_ES
dc.description.references De Biase, D., Visani, M., Malapelle, U., Simonato, F., Cesari, V., Bellevicine, C., … Tallini, G. (2013). Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy). PLoS ONE, 8(12), e83607. doi:10.1371/journal.pone.0083607 es_ES
dc.description.references Lozano, M. D., Labiano, T., Echeveste, J., Gurpide, A., Martín‐Algarra, S., Zhang, G., … Palma, J. F. (2014). Assessment of EGFR and KRAS mutation status from FNAs and core‐needle biopsies of non‐small cell lung cancer. Cancer Cytopathology, 123(4), 230-236. doi:10.1002/cncy.21513 es_ES
dc.description.references Hantson, I., Dooms, C., Verbeken, E., Vandenberghe, P., Vliegen, L., Roskams, T., … Vansteenkiste, J. (2014). Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study. Translational Respiratory Medicine, 2(1). doi:10.1186/s40247-014-0009-0 es_ES
dc.description.references Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013). Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 10(8), 472-484. doi:10.1038/nrclinonc.2013.110 es_ES
dc.description.references Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011). Cell-free nucleic acids as biomarkers in cancer patients. Nature Reviews Cancer, 11(6), 426-437. doi:10.1038/nrc3066 es_ES
dc.description.references Sundaresan, T. K., Sequist, L. V., Heymach, J. V., Riely, G. J., Ja nne, P. A., Koch, W. H., … Haber, D. A. (2015). Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clinical Cancer Research, 22(5), 1103-1110. doi:10.1158/1078-0432.ccr-15-1031 es_ES
dc.description.references Chia, P. L., Do, H., Morey, A., Mitchell, P., Dobrovic, A., & John, T. (2016). Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment. Lung Cancer, 98, 29-32. doi:10.1016/j.lungcan.2016.05.003 es_ES
dc.description.references Alix-Panabières, C., & Pantel, K. (2013). Circulating Tumor Cells: Liquid Biopsy of Cancer. Clinical Chemistry, 59(1), 110-118. doi:10.1373/clinchem.2012.194258 es_ES
dc.description.references Yao, Y., Liu, J., Li, L., Yuan, Y., Nan, K., Wu, X., … Jiang, Z. (2016). Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer. Oncotarget, 8(2), 2130-2140. doi:10.18632/oncotarget.12883 es_ES
dc.description.references Camps, C., Jantus-Lewintre, E., Cabrera, A., Blasco, A., Sanmartín, E., Gallach, S., … Sirera, R. (2011). The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer, 72(3), 365-369. doi:10.1016/j.lungcan.2010.09.005 es_ES
dc.description.references Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., … Rosenfeld, N. (2013). Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. New England Journal of Medicine, 368(13), 1199-1209. doi:10.1056/nejmoa1213261 es_ES
dc.description.references Ankeny, J. S., Court, C. M., Hou, S., Li, Q., Song, M., Wu, D., … Tomlinson, J. S. (2016). Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. British Journal of Cancer, 114(12), 1367-1375. doi:10.1038/bjc.2016.121 es_ES
dc.description.references Tan, C. R. C., Zhou, L., & El-Deiry, W. S. (2016). Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons. Current Colorectal Cancer Reports, 12(3), 151-161. doi:10.1007/s11888-016-0320-y es_ES
dc.description.references Malapelle, U., Pisapia, P., Rocco, D., Smeraglio, R., di Spirito, M., Bellevicine, C., & Troncone, G. (2016). Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. Translational Lung Cancer Research, 5(5), 505-510. doi:10.21037/tlcr.2016.10.08 es_ES
dc.description.references Sirera, R., Bremnes, R. M., Cabrera, A., Jantus-Lewintre, E., Sanmartín, E., Blasco, A., … Camps, C. (2011). Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 6(2), 286-290. doi:10.1097/jto.0b013e31820189a5 es_ES
dc.description.references Lianidou, E. S., Mavroudis, D., & Georgoulias, V. (2013). Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. British Journal of Cancer, 108(12), 2426-2432. doi:10.1038/bjc.2013.265 es_ES
dc.description.references Diamandis, E. P., Pantel, K., Scher, H. I., Terstappen, L., & Lianidou, E. (2011). Circulating Cancer Cells and Their Clinical Applications. Clinical Chemistry, 57(11), 1478-1484. doi:10.1373/clinchem.2011.166678 es_ES
dc.description.references Karachaliou, N., Mayo-de las Casas, C., Queralt, C., de Aguirre, I., Melloni, B., Cardenal, F., … Rosell, R. (2015). Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncology, 1(2), 149. doi:10.1001/jamaoncol.2014.257 es_ES
dc.description.references Pasquale, R., Fenizia, F., Esposito Abate, R., Sacco, A., Esposito, C., Forgione, L., … Normanno, N. (2015). Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. Pharmacogenomics, 16(10), 1135-1148. doi:10.2217/pgs.15.45 es_ES
dc.description.references Thress, K. S., Brant, R., Carr, T. H., Dearden, S., Jenkins, S., Brown, H., … Barrett, J. C. (2015). EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer, 90(3), 509-515. doi:10.1016/j.lungcan.2015.10.004 es_ES
dc.description.references Kimura, H., Ohira, T., Uchida, O., Matsubayashi, J., Shimizu, S., Nagao, T., … Nishio, K. (2014). Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. Lung Cancer, 83(3), 329-333. doi:10.1016/j.lungcan.2013.12.012 es_ES
dc.description.references Benlloch, S., Botero, M. L., Beltran-Alamillo, J., Mayo, C., Gimenez-Capitán, A., de Aguirre, I., … Taron, M. (2014). Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial. PLoS ONE, 9(2), e89518. doi:10.1371/journal.pone.0089518 es_ES
dc.description.references Wu, Y.-L., Zhou, C., Liam, C.-K., Wu, G., Liu, X., Zhong, Z., … Zuo, Y. (2015). First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Annals of Oncology, 26(9), 1883-1889. doi:10.1093/annonc/mdv270 es_ES
dc.description.references Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., … Cadranel, J. (2014). Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Annals of Oncology, 25(1), 126-131. doi:10.1093/annonc/mdt418 es_ES
dc.description.references Yasuda, H., Kobayashi, S., & Costa, D. B. (2012). EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. The Lancet Oncology, 13(1), e23-e31. doi:10.1016/s1470-2045(11)70129-2 es_ES
dc.description.references Oxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., … Jänne, P. A. (2016). Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 34(28), 3375-3382. doi:10.1200/jco.2016.66.7162 es_ES
dc.description.references Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., … Halmos, B. (2005). EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 352(8), 786-792. doi:10.1056/nejmoa044238 es_ES
dc.description.references Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., … Pao, W. (2006). Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. Clinical Cancer Research, 12(21), 6494-6501. doi:10.1158/1078-0432.ccr-06-1570 es_ES
dc.description.references Costa, D. B., Schumer, S. T., Tenen, D. G., & Kobayashi, S. (2008). Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations. Journal of Clinical Oncology, 26(7), 1182-1184. doi:10.1200/jco.2007.14.9039 es_ES
dc.description.references Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., … Oxnard, G. R. (2015). Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. Nature Medicine, 21(6), 560-562. doi:10.1038/nm.3854 es_ES
dc.description.references Bean, J., Riely, G. J., Balak, M., Marks, J. L., Ladanyi, M., Miller, V. A., & Pao, W. (2008). Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma. Clinical Cancer Research, 14(22), 7519-7525. doi:10.1158/1078-0432.ccr-08-0151 es_ES
dc.description.references Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., … Janne, P. A. (2007). MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science, 316(5827), 1039-1043. doi:10.1126/science.1141478 es_ES


Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem